Triple combination therapy: Marketed

Researchers from Amsterdam's National AIDS Therapy Evaluation Center presented 48-week results from the 2-year Atlantic Study, which compares the combination of Bristol-Myers Squibb's Zerit stavudine d4T and Videx didanosine ddI nucleoside analogs with either BioChem Pharma's Epivir lamivudine 3TC, Boehringer Ingelheim's Viramune nevirapine non-nucleoside reverse transcriptase inhibitor (NNRTI), or Merck's Crixivan indinavir protease inhibitor. Of 298 enrolled patients, 235 had completed 48 weeks and viral load data for 181 of those was available. Viral load was below 50 HIV RNA copies/mL in 57 percent of the indinavir group, 51 percent of the nevirapine group and 49 percent of the 3TC group. ...